Holen Sie sich die Stockscreener-App
11.27
1.91%
-0.22
Schlusskurs vom Vortag:
$11.49
Offen:
$11.59
24-Stunden-Volumen:
58,059
Relative Volume:
0.30
Marktkapitalisierung:
$341.92M
Einnahmen:
$6.67M
Nettoeinkommen (Verlust:
$-47.55M
KGV:
-7.5133
EPS:
-1.5
Netto-Cashflow:
$-17.44M
1W Leistung:
-8.71%
1M Leistung:
+19.77%
6M Leistung:
-20.86%
1J Leistung:
+2,104%
1-Tages-Spanne:
$10.92
$11.59
1-Wochen-Bereich:
$10.61
$12.44
52-Wochen-Spanne:
$8.72
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
Firmenname
Crescent Biopharma Inc
Sektor
Branche
Telefon
617-430-5595
Adresse
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
11.23 | 349.83M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.43 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.76 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
725.02 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.64 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.26 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Piper Sandler | Overweight |
| 2026-01-21 | Eingeleitet | Guggenheim | Buy |
| 2025-08-25 | Eingeleitet | Jefferies | Buy |
| 2025-08-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-14 | Eingeleitet | Wedbush | Outperform |
| 2025-06-25 | Eingeleitet | Stifel | Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-11 | Eingeleitet | Noble Capital Markets | Outperform |
| 2024-07-26 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-22 | Eingeleitet | CapitalOne | Overweight |
| 2021-11-12 | Hochstufung | Jefferies | Hold → Buy |
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-11-14 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-05 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-12-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-07-26 | Eingeleitet | SunTrust | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-03-17 | Bestätigt | Stifel | Buy |
Alle ansehen
Crescent Biopharma Inc Aktie (CBIO) Neueste Nachrichten
HC Wainwright Issues Optimistic Estimate for CBIO Earnings - MarketBeat
GLYC SEC FilingsGlycomimetics 10-K, 10-Q, 8-K Forms - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Given New $22.00 Price Target at HC Wainwright - Defense World
Crescent Biopharma (NASDAQ: CBIO) registers 19.58M resale shares after $185M placement - Stock Titan
CBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Price Target Lowered to $22.00 at HC Wainwright - MarketBeat
H.C. Wainwright cuts Crescent Biopharma stock price target to $22 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Crescent Biopharma stock price target to $22 - Investing.com Nigeria
Crescent Biopharma (CBIO) Posts US$10.8m Q4 Revenue Against Heavy Losses Challenging Bullish Narratives - simplywall.st
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Stifel cuts Crescent Biopharma stock price target on equity financing - Investing.com South Africa
Stifel cuts Crescent Biopharma stock price target on equity financing By Investing.com - Investing.com Canada
Crescent Biopharma: Q4 Earnings Snapshot - theheraldreview.com
Crescent Biopharma Inc recently disclosed that certain revenues recognized in its 2025 financial report actually originate from a $20 million upfront payment made by Kelun-Biotech under a licensing agreement between the two parties for the core asset Cr-00 - Bitget
CBIO: Expanded oncology pipeline and strong cash position support multiple clinical milestones into 2028 - TradingView
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent ... - Bluefield Daily Telegraph
Crescent Biopharma (Nasdaq: CBIO) ramps R&D with $185M raise and 2025 loss - Stock Titan
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Crescent Biopharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Crescent Biopharma (NASDAQ:CBIO) Stock Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Crescent Biopharma: Fourth Quarter Financial Results Overview - Bitget
Crescent Biopharma to Present at March Investor Conferences - Bitget
Cancer-focused biotech Crescent Biopharma plans March investor talks in Boston and Miami - Stock Titan
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors - ADVFN
Crescent Biopharma announces grants of inducement awards - TipRanks
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
Crescent Biopharma doses first patient in ASCEND cancer trial - Investing.com Nigeria
Should I Buy CBIO? CBIO 2026 AnalysisIntellectia AI™ - Intellectia AI
Crescent Biopharma announces first patient dosed in Ascend Phase 1/2 clinical trial of CR-001 - marketscreener.com
Crescent Biopharma Announces First Patient Dosed In Ascend Phase 1/2 Clinical Trial Of CR-001 - TradingView
Crescent Biopharma Doses First Patient in ASCEND Trial of Solid Tumor Treatment - marketscreener.com
Crescent Biopharma doses first patient in ASCEND cancer trial By Investing.com - Investing.com Canada
Experimental cancer antibody CR-001 enters global trial in advanced solid tumors - Stock Titan
Mineurs de cuivre, Fresh Del Monte Produce, Crescent Biopharma - TradingView
Will Crescent Biopharma Inc. (GKO0) stock remain on Wall Street radarWeekly Loss Report & Safe Entry Momentum Stock Tips - mfd.ru
Is Crescent Biopharma Inc. (GKO0) stock in buy zone after pullback2025 Technical Patterns & Weekly High Return Forecasts - mfd.ru
CBIO: Global oncology pipeline advances with CR-001 and ADCs, backed by strong funding and partnerships - TradingView
FMR LLC's Strategic Acquisition of Crescent Biopharma Inc Shares - GuruFocus
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Clinical-stage biotech Crescent Biopharma joins Guggenheim summit Feb. 12 - Stock Titan
Crescent Biopharma (CBIO) Price Target Increased by 10.69% to 29.92 - Nasdaq
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Upgraded to "Strong-Buy" at Piper Sandler - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Upgraded at Wall Street Zen - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Upgraded by Guggenheim to Strong-Buy Rating - MarketBeat
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Guggenheim Initiates Crescent Biopharma(CBIO.US) With Buy Rating, Announces Target Price $35 - 富途资讯
Crescent Biopharma Advances CR-001 Cancer Trial Into First-in-Human Stage - TipRanks
Finanzdaten der Crescent Biopharma Inc-Aktie (CBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):